Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.37 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.34 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL214837 | 1.00 | LMNA (0.46) | LMNAPMP22NLRP3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL14744098 | 1.00 | LMNA (0.46) | LMNAPMP22NLRP3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL320242 | 1.00 | LMNA (0.46) | LMNAPMP22NLRP3CYP3A4CYP2D6 | |
| SCHEMBL3297 | 0.97 | CYP3A4 (0.44) | LMNAPMP22NLRP3CYP3A4CYP2D6 | |
| SCHEMBL206710 | 0.97 | CYP3A4 (0.44) | LMNAPMP22NLRP3CYP3A4CYP2D6 | |
| SCHEMBL320243 | 0.97 | CYP3A4 (0.44) | LMNAPMP22NLRP3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL23455679 | 0.93 | CYP3A4 (0.42) | LMNAPMP22NLRP3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL21612238 | 0.93 | CYP3A4 (0.42) | LMNAPMP22NLRP3CYP3A4CYP2D6 | |
| SCHEMBL7447781 | 0.91 | CYP3A4 (0.41) | LMNAPMP22NLRP3CYP3A4CYP2D6 | |
| Acetic Acid SCHEMBL5168057 | 0.91 | CYP3A4 (0.41) | LMNAPMP22NLRP3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 374 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528812-B | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-06-03 | — | — | CN | claimed |
| CN-119528812-A | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-02-28 | — | — | CN | claimed |
| CN-110269858-A | It is a kind of to treat twin medicine of cerebral arterial thrombosis and preparation method thereof | 贵州医科大学 | 2019-09-24 | — | — | CN | claimed |
| CN-108409781-A | One kind six vanadic acid-l-Alanine tert-butyl ester derivative and the preparation method and application thereof | 湖北工业大学 | 2018-08-17 | — | — | CN | claimed |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-119528812-B | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-06-03 | — | — | CN | disclosed |
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119752217-A | Narrow emission dyes, compositions comprising the same, and methods of making and using the same | 尼尔瓦纳科学股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2025068919-A1 | METAL-CONTAINING PEPTOID MEMBRANES FOR HYDROLYSIS OF ORGANOPHOSPHATES | BATTELLE MEMORIAL INSTITUTE (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250099947-A1 | METAL-CONTAINING PEPTOID MEMBRANES FOR HYDROLYSIS OF ORGANOPHOSPHATES | BATTELLE MEMORIAL INSTITUTE | 2025-03-27 | — | — | US | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| CN-119528812-A | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-02-28 | — | — | CN | disclosed |
| WO-1998035982-A1 | COMPOUNDS FOR USE IN ADEPT | ZENECA LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
| WO-1998019705-A1 | BRANCHED PEPTIDE LINKERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-14 | — | — | WO | disclosed |
| WO-1997014417-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| EP-0715623-A1 | PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1996-06-12 | — | — | EP | disclosed |
| US-5489594-A | ANTICOAGULANTS | G. D. SEARLE & CO. (US) | 1996-02-06 | — | — | US | disclosed |
| US-5430043-A | Platelet aggregation inhibitors | G. D. SEARLE & CO. (US) | 1995-07-04 | — | — | US | disclosed |
| WO-1995006038-A1 | PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | disclosed |
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | GRIN2D 2531/4885GRIN3B 3653/4885GRIN1 2316/4885 |
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | GRIN2D 2593/4885GRIN3B 1469/4885GRIN1 1989/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | GRIN2D 3730/4885GRIN3B 3762/4885GRIN1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.